Evotec and APEIRON Biologics start next project on the Cbl-b target

24-Oct-2011 - Germany

Evotec AG and Apeiron Biologics AG announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.

Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively enhance anti-tumor activities both for tumor antigen-specific cells and for those recognizing general features of tumor cells.

Evotec will apply their skills and proprietary technologies in cellular assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with Cbl-b. The aim of the collaboration will be to take compounds identified by Evotec as being active against this target or other relevant targets and further jointly optimize them as basis for formal preclinical and clinical development.

No financial details are disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances